Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Tax Provisions (2020 - 2025)

Historic Tax Provisions for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to -$262000.0.

  • Mirum Pharmaceuticals' Tax Provisions fell 17550.43% to -$262000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $593000.0, marking a year-over-year decrease of 6761.33%. This contributed to the annual value of $1.0 million for FY2024, which is 393.54% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Tax Provisions stood at -$262000.0 for Q3 2025, which was down 17550.43% from $402000.0 recorded in Q2 2025.
  • Mirum Pharmaceuticals' Tax Provisions' 5-year high stood at $1.0 million during Q1 2025, with a 5-year trough of -$6.6 million in Q2 2022.
  • Over the past 5 years, Mirum Pharmaceuticals' median Tax Provisions value was $140000.0 (recorded in 2022), while the average stood at -$167315.8.
  • Its Tax Provisions has fluctuated over the past 5 years, first crashed by 5982727.27% in 2022, then soared by 181538.46% in 2023.
  • Mirum Pharmaceuticals' Tax Provisions (Quarter) stood at $12000.0 in 2021, then soared by 1066.67% to $140000.0 in 2022, then surged by 60.71% to $225000.0 in 2023, then crashed by 356.0% to -$576000.0 in 2024, then soared by 54.51% to -$262000.0 in 2025.
  • Its Tax Provisions was -$262000.0 in Q3 2025, compared to $402000.0 in Q2 2025 and $1.0 million in Q1 2025.